Compare · GDTC vs NVO
GDTC vs NVO
Side-by-side comparison of CytoMed Therapeutics Limited (GDTC) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GDTC and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 19482.0x GDTC ($11.1M).
- NVO has hit the wire 9 times in the past 4 weeks while GDTC has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for GDTC).
- Company
- CytoMed Therapeutics Limited
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $11.1M
- $215.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 0
- 9
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GDTC
- Amendment: Director Choo Chee Kong bought $300,000 worth of ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED (200,000 units at $1.50), increasing direct ownership by 46% to 630,324 units (SEC Form 4)
- SEC Form 4 filed by Director Choo Chee Kong
- SEC Form 6-K filed by CytoMed Therapeutics Limited
- Director Choo Chee Kong bought $128,778 worth of Ordinary Shares (112,000 units at $1.15), increasing direct ownership by 35% to 430,324 units (SEC Form 4)
- SEC Form 6-K filed by CytoMed Therapeutics Limited
- New insider Toh Keng Kiat claimed ownership of 4,000 units of Ordinary Shares (SEC Form 3)
- New insider Choo Chee Kong claimed ownership of 2,587,746 units of Ordinary Shares (SEC Form 3)
- New insider Yew Chak Hua claimed ownership of 2,469 units of Ordinary Shares (SEC Form 3)
- SEC Form 3 filed by new insider Leong Mark Kei Wei
- New insider Goh Yvonne claimed ownership of 25,781 units of Ordinary Shares (SEC Form 3)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S